|
1 Indications And Usage Promacta Is A Thrombopoietin Receptor Agonist Indicated: For The Treatment Of Thrombocytopenia In Adult And Pediatric Patients 1 Year And Older With Chronic Immune Thrombocytopenia (Itp) Who Have Had An Insufficient Response To Corticosteroids, Immunoglobulins, Or Splenectomy. Promacta Should Be Used Only In Patients With Itp Whose Degree Of Thrombocytopenia And Clinical Condition Increase The Risk For Bleeding. ( 1.1 ) For The Treatment Of Thrombocytopenia In Patients With Chronic Hepatitis C To Allow The Initiation And Maintenance Of Interferon-Based Therapy. Promacta Should Be Used Only In Patients With Chronic Hepatitis C Whose Degree Of Thrombocytopenia Prevents The Initiation Of Interferon-Based Therapy Or Limits The Ability To Maintain Interferon-Based Therapy. ( 1.2 ) In Combination With Standard Immunosuppressive Therapy For The First-Line Treatment Of Adult And Pediatric Patients 2 Years And Older With Severe Aplastic Anemia. ( 1.3 ) For The Treatment Of Patients With Severe Aplastic Anemia Who Have Had An Insufficient Response To Immunosuppressive Therapy. ( 1.3 ) Limitations Of Use: Promacta Is Not Indicated For The Treatment Of Patients With Myelodysplastic Syndrome (Mds). ( 1.4 ) Safety And Efficacy Have Not Been Established In Combination With Direct-Acting Antiviral Agents Used Without Interferon For Treatment Of Chronic Hepatitis C Infection. ( 1.4 ) 1.1 Treatment Of Thrombocytopenia In Patients With Chronic Immune Thrombocytopenia Promacta Is Indicated For The Treatment Of Thrombocytopenia In Adult And Pediatric Patients 1 Year And Older With Chronic Immune Thrombocytopenia (Itp) Who Have Had An Insufficient Response To Corticosteroids, Immunoglobulins, Or Splenectomy. Promacta Should Be Used Only In Patients With Itp Whose Degree Of Thrombocytopenia And Clinical Condition Increase The Risk For Bleeding. 1.2 Treatment Of Thrombocytopenia In Patients With Hepatitis C Infection Promacta Is Indicated For The Treatment Of Thrombocytopenia In Patients With Chronic Hepatitis C To Allow The Initiation And Maintenance Of Interferon-Based Therapy. Promacta Should Be Used Only In Patients With Chronic Hepatitis C Whose Degree Of Thrombocytopenia Prevents The Initiation Of Interferon-Based Therapy Or Limits The Ability To Maintain Interferon-Based Therapy. 1.3 Treatment Of Severe Aplastic Anemia Promacta Is Indicated In Combination With Standard Immunosuppressive Therapy (Ist) For The First-Line Treatment Of Adult And Pediatric Patients 2 Years And Older With Severe Aplastic Anemia. Promacta Is Indicated For The Treatment Of Patients With Severe Aplastic Anemia Who Have Had An Insufficient Response To Immunosuppressive Therapy. 1.4 Limitations Of Use Promacta Is Not Indicated For The Treatment Of Patients With Myelodysplastic Syndromes (Mds) [See Warnings And Precautions (5.3)] . Safety And Efficacy Have Not Been Established In Combination With Direct-Acting Antiviral Agents Used Without Interferon For Treatment Of Chronic Hepatitis C Infection.
|